Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

uch patients are characterized by presence of chromosomal abnormalities (i.e., deletions of chromosome 17p or 11q) or short remissions (less than 3 years) after standard chemo-immunotherapy. To develop an alternative therapy regimen for this patient population, researchers explored the combination of ibrutinib and the anti-CD20 antibody rituximab in high-risk CLL.

In this Phase II study conducted at The University of Texas MD Anderson Cancer Center in Houston, ibrutinib was given in combination with rituximab to evaluate its potential to accelerate and improve CLL patient responses. Forty patients were treated with 420 mg of ibrutinib daily in combination with weekly rituximab for four weeks, followed by ibrutinib daily plus monthly rituximab until month six, followed by single-agent ibrutinib.

Positive responses to therapy were shown among the vast majority of treated patients. At four months of follow-up, the overall response rate was 85 percent and almost all (38 of 40) patients continued on therapy without disease progression. Of the 20 patients evaluable for early response, 17 achieved a partial remission. Patient health questionnaires also noted improvements in health and the quality of life of all treated patients.

Overall, the regimen was well-tolerated among participants, with little severe toxicity that was largely unrelated and short in duration. After treatment with ibrutinib-rituximab (iR) combination therapy, most cases of early lymphocytosis (increase in white blood cells that is a sign of infection), due to the ibrutinib-induced shift of CLL cells from lymph node tissues into the blood, peaked early and resolved; at four months of follow-up, only three treated patients had lymphocytosis that had not yet resolved. This shorter lymphocytosis duration, when compared to single-agent use of ibrutinib, is presumably related to the addition of rituximab.

"We know that high-risk CLL patients struggle with the effects of
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Well-known San Diego ... largest, family-owned low cost service and repair companies. For 35 years, they have ... growing their company to meet the demands of the changing technological environment. ...
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... Orange County, CA (PRWEB) , ... July 30, ... ... of home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, ... team as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent ...
(Date:7/30/2015)... ... 30, 2015 , ... 24/7 Care At Home, a high-quality provider of comprehensive ... that the Centers for Medicare and Medicaid (CMS) have awarded its agency the highest ... Care At Home’s agency is one of three top Orange County agencies to earn ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
Breaking Medicine News(10 mins):Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Beachside Nursing Center Releases New Video 2
... the House,Committee on Foreign Relations will consider the renewal ... Research Council (FRC),President Tony Perkins released the following statement ... Lantos (D-CA):, "The Lantos bill would change PEPFAR ... be tilted toward those who perform and promote,abortion under ...
... time for deployment of Wi-Fi RTLS, in existing ... tag, BROOKFIELD, Wis., Feb. 7 RF ... solutions for the Healthcare Industry,since 1987, will demonstrate ... Booth 2101. The new PinPoint(R) Peer-to-Peer Wi-Fi,Tag optimizes ...
... 2008 Income Tax Check-Off,Campaign, HERSHEY, Pa., Feb. ... the state,s Income Tax Check-Off,for Breast and Cervical ... in grants that will be awarded to Pennsylvania-based,researchers ... a.m., the,Pennsylvania Breast Cancer Coalition will be holding ...
... A protein naturally produced and secreted by the body can ... killed more than 8,000 people in the United States last ... of the journal Cell, a publication of Cell Press. ... produced and delivered to tumors, it might serve as a ...
... National Institute on Drug Abuse has awarded University of ... million grant to develop what may become the first ... , The researchers believe this ambitious program may ultimately ... the director of UTMB,s Center for Addiction Research, Kathryn ...
... teams at a leading New York,healthcare communications group are ... day-long Tech Fit fair on Tuesday, February 12, 2008, ... lower,Manhattan., According to Sam Welch, SSHCG president, "Tech ... the latest innovation in SSHCG,s ongoing program of,digital training, ...
Cached Medicine News:Health News:At HIMSS '08, RF Technologies(R) Will Host LIVE! Demonstrations of PinPoint(R) Peer-to-Peer Wi-Fi RTLS - a Breakthrough in Location-Aware Solutions 2Health News:At HIMSS '08, RF Technologies(R) Will Host LIVE! Demonstrations of PinPoint(R) Peer-to-Peer Wi-Fi RTLS - a Breakthrough in Location-Aware Solutions 3Health News:The Pennsylvania Breast Cancer Coalition Announces 2008 Breast Cancer Income Tax Check-Off Grant Recipients 2Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3Health News:UTMB wins $3.4 million federal grant to study addiction-recovery drugs 2Health News:UTMB wins $3.4 million federal grant to study addiction-recovery drugs 3Health News:Google, Yahoo 'Personal Trainers' Strengthen Digital Delts, Partner With Saatchi & Saatchi Healthcare Communications Group Teams in Tech Circuit Training 2Health News:Google, Yahoo 'Personal Trainers' Strengthen Digital Delts, Partner With Saatchi & Saatchi Healthcare Communications Group Teams in Tech Circuit Training 3
(Date:7/30/2015)... , July 30, 2015  Growth of the U.S. ... they bring former prescription users to the OTC market. ... forecasts robust Rx-to-OTC switch activity over the next ... along with many new brands entering the market into ... the next five years (even those with low to ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... ASHBURN, Va. , July 13 Innocoll, Inc. announced ... Protocol Assessment (SPA) for a proposed phase 3 clinical trial to ... the adjuvant treatment of infected diabetic foot ulcers. , ... The protocol was developed ...
... 12 Crux Biomedical® was named one of "50 Companies to ... survey, conducted by Medical Device and Diagnostics Industry (MD+DI), was published in ... to identify firms that have either achieved success or have the potential ... , , ...
Cached Medicine Technology:Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections 2Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections 3Crux Biomedical Named One of Top 50 Companies to Watch 2
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... of three separate components: an exchange rod, a ... transparent trocar sleeve. The exchange rod is a ... long. The dilating obturator is tapered and threaded ... opening created by the 10/11mm or the 12mm ...
Medicine Products: